$CGEN

Compugen Ltd. (NASDAQ:CGEN) is seen as Buy and the price target at 23.

The stock finished at 13.82-0.70 (-4.82%) at close: 4:00p EDT and 13.90+0.08 (0.58%) Pre-Market:5:12a EDT

All of our Key indicators have turned Very Bullish across the board since 16 April. Key Support is at 11.79 and the Resistance is Nil.

Compugen Ltd. is a therapeutic discovery company engaged in the research, development, and commercialization of therapeutic and product candidates in Israel, the US, and EU.

The companys therapeutic pipeline consists of immuno-oncology programs against novel drug targets, including T cell immune checkpoints and other early-stage immuno-oncology programs focusing on myeloid target.

Its product pipeline consists of COM701, a therapeutic antibody that is in phase I clinical trials for PVRIG; BAY 1905254, a therapeutic antibody that is in phase I clinical trials for ILDR2; and COM902, a therapeutic immuno-oncology antibody for TIGIT program.

Compugen Ltd. has a collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY)to evaluate the safety of COM701 in combination with Bristol-Myers Squibbs programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and license agreement with MedImmune Limited for the development of bi-specific and multi-specific immuno-oncology antibody products.

The company was incorporated in Y 1993 and is HQd in Holon, Israel.

Have a healthy day, Keep the Faith!

BMY, CGEN, commercialization, development, discovery, immunology, oncology, product, research, therapeutic

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of The Red Roadmasters Technical Report on the US Major Market Indices, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Go here to see the original:
Sitting on a Pile of Cash? Here is a Company in the Immunology Field with a 77% Upside Target Mid-term - Live Trading News